Drug combo for advanced kidney cancer, preserving the kidney
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) to treat HER2-positive high-risk upper tract urothelial cancer, aiming to save the kidney instead of removing it. The drugs target cancer cells and boost the immune system to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with high-risk cancer in the upper urinary tract (kidney or ureter)
- Your cancer is HER2-positive (a specific protein marker on the cells)
- You have not had prior chemotherapy, immunotherapy, or HER2-targeted therapy for this cancer
- You have not had surgery to remove your entire kidney on the affected side
- You have not had cancer that has spread to distant organs, and you have good overall health (ECOG 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial is testing a kidney-sparing treatment approach for people with high-risk cancer in the kidney or ureter that has not spread. It aims to control the cancer while saving as much of the kidney's function as possible.
This study tests whether combining two drugs—toripalimab (an immunotherapy that boosts your immune system) and 9MW2821 (a targeted drug that delivers treatment directly to cancer cells)—before surgery helps shrink tumors and improves outcomes for people with upper tract urothelial cancer. The goal is to see if this combination is safe and effective before the kidney and ureter are removed.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.